WALTHAM, Massachusetts, August 21, 2026, 16:25 EDT — Shares of Werewolf Therapeutics doubled in value after the company merged with Ambros, with Werewolf shareholders holding 6.8% of the combined entity.
- Shares of Werewolf ended the session up 102.6% following the announcement of its merger with Ambros.
- Current Werewolf shareholders are anticipated to hold a 6.8% stake in the merged company.
- A simultaneous $150 million PIPE aims to finance the pivotal CRPS program through 2029.
Shares of Werewolf Therapeutics, Inc. NASDAQ:HOWL surged over 100% on Friday following the announcement of its planned merger with private company Ambros Therapeutics. The stock finished at $0.8735, a gain of 102.6%, with trading volume reaching 290.4 million shares — nearly 197 times its average over the past three months.
The main headline increase conceals the core compromise of the agreement. Existing Werewolf shareholders are projected to hold only 6.8% of the merged entity. Ambros investors and PIPE backers would possess the other 93.2%.
The market value on Friday stood at $42.5 million, which is roughly 10.6% lower than Werewolf’s agreed pre-financing valuation of $47.5 million. That gap is modest compared to the stock’s intraday movement. Shares ended the session down 16.8% from their $1.05 peak.
| Friday market measure | HOWL | Investor read-through |
|---|---|---|
| Closing price | $0.8735 | Jumped 102.6% on the day |
| Intraday range | $0.86–$1.05 | Finished 16.8% under session high |
| Volume | 290.4 million | Turnover was 196.9 times its three-month average |
| Market capitalization | $42.5 million | Stands 10.6% below Werewolf deal valuation |
The all-share deal gives Ambros a pre-financing valuation of $500 million, while Werewolf is assigned a $47.5 million value. The merger is set to be completed alongside a $150 million private placement, jointly led by RA Capital Management and Janus Henderson Investors.
| Stakeholder group | Expected ownership | Economic role |
|---|---|---|
| Ambros shareholders | 71.7% | Supply neridronate and operational framework |
| PIPE investors | 21.5% | Inject $150 million fresh capital |
| Pre-merger Werewolf shareholders | 6.8% | Bring public market status, net cash and remaining assets |
The merged company will operate under the Ambros Therapeutics brand and intends to list as NASDAQ:AMBX. Headquarters are set to relocate to San Diego. The deal aims to close by the first quarter of 2027, pending shareholder approval, a valid registration statement, and clearance from Nasdaq.
Ambros is positioning neridronate as its primary asset. The drug is currently undergoing the pivotal CRPS-RISE Phase 3 study for warm complex regional pain syndrome type 1. Initial results are anticipated in 2028.
| Program measure | Verified status | Next investor marker |
|---|---|---|
| Lead indication | Warm CRPS-1 | Could become first FDA-approved treatment for condition |
| Pivotal study | CRPS-RISE Phase 3 | Headline results anticipated in 2028 |
| Regulatory designations | Breakthrough Therapy, Fast Track and Orphan Drug | Approval not assured by these designations |
| Estimated U.S. incidence | Approximately 65,000 new cases per year | Market opportunity hinges on diagnosis rates and adoption |
| Pro forma cash runway | Extends through first half of 2029 | Reflects expected PIPE funding |
Ambros Chief Executive Jay Hagan stated, “We expect to be fully funded through potentially value-generating topline results.” As a result, the financing moves the near-term equity narrative away from Werewolf’s cash concerns and focuses it instead on a significant upcoming clinical data milestone. Company announcement
Werewolf stated it had $22.0 million in cash as of June 30 and flagged significant uncertainty over its ability to remain a going concern over the next 12 months. The company reduced research expenditures amid capital preservation efforts during its strategic review.
| Legacy Werewolf measure | Amount | Why it matters |
|---|---|---|
| Cash as of June 30 | $22.0 million | Figures into the transaction’s net-cash calculation |
| Research and development expense in Q2 | $6.2 million | Lower than $13.1 million posted in the previous year |
| General and administrative expense in Q2 | $7.7 million | Higher than $4.4 million seen during the strategic assessment |
| EMD Serono asset sale proceeds | $28 million upfront; $5 million post-transfer | Could affect cash balances and the legacy CVR |
Pre-merger shareholders are set to obtain a contingent value right as well. This right pertains to select proceeds from Werewolf’s former assets. The firm has divested segments of its INDUCER and INDUKINE technology to EMD Serono, securing an upfront payment of $28 million, with an additional $5 million to be paid following the completion of the technology transfer.
Legacy analyst price targets provide limited direction following Friday’s deal. As of August 5, a consensus from seven analysts showed a Hold rating and an average price target of $3.75. These assessments were issued before the merger, the PIPE, and the intended move to neridronate.
| Legacy recommendation | Analyst count | Share of seven |
|---|---|---|
| Buy | 2 | 28.6% |
| Hold | 4 | 57.1% |
| Sell | 1 | 14.3% |
| Consensus / average target | Hold / $3.75 | Registered prior to the merger news |
Risks: The merger may not complete or could proceed under altered terms. Final ownership is contingent on net cash at closing. Neridronate is still investigational; an unsuccessful Phase 3 trial could significantly reduce the value of the combined entity.
Upcoming key disclosures include the merger registration statement and a revised net-cash estimate. Investors are advised to monitor for fresh analyst coverage focusing on Ambros. Friday’s rally reduced the gap to the agreed value, but trial risk remains.
Related articles: Biotechnology
